Skip to main content
. Author manuscript; available in PMC: 2011 Sep 13.
Published in final edited form as: J Med Chem. 2008 Aug 19;51(17):5285–5296. doi: 10.1021/jm800321h

Figure 2.

Figure 2

Differential cytotoxicity in MDA-MB-231 and Hs58.Fs cells are a model platform for screening FASTE inhibitors, as shown by the pharmacological and siRNA inhibition of FAS. MDA-MB-231 tumor cells and primary cultures of Hs58.5s fibroblasts were exposed to 100 nM FAS siRNA or nonsilencing control siRNA and 25 μM orlistat or vehicle control for 72 h. Cellular cytotoxicity was monitored by measuring DNA fragmentation. Values are means ± SE of four samples per treatment group.